W
WAVEMAN · COMPANY
CYTK · Cytokinetics Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

CYTK

CYTOKINETICS INC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001061983
CONGRESS · 1FORM 144 · 7☆ WATCH
INSIDER NET · 180D
-$28.6M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
329
13F, latest reported quarter
REVENUE GROWTH
+376.6%
XBRL, annual
NET MARGIN
-891.6%
CONVERSIONS · 180D
34
codes C/M, not in net · $5.4M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$28.6M over 180 days
-$11.9M over 90 days
below 91% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
329 funds added or opened last quarter
more than 94% of Pharma & Biotech
REVENUE
+376.6% year over year
more than 92% of Pharma & Biotech
MARGIN
-891.6% net margin
below 87% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
11.0% of shares outstanding short · 9.6 days to cover · settled 2026-07-31
more than 80% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$28.6M across 8 people in 180 days.
329 funds added or opened positions in the latest 13F quarter, of 487 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +46.6%
+46.6%12M
-4%+23%+49%+76%2025-092025-102025-122026-032026-052026-072026-09 2025-12-05 · Callos Andrew sold $3.5M2026-06-24 · Lee Sung sold $3.2M2025-12-01 · Kaye Edward M. MD sold $1.9M2026-05-05 · Lee Sung sold $1.8M2026-05-05 · HENDERSON JOHN T sold $1.5M2026-03-17 · Blum Robert I sold $1.5M2025-12-22 · WIERENGA WENDELL sold $1.3M2026-07-01 · Callos Andrew sold $1.3M2026-07-30 · Callos Andrew sold $1.1M2026-06-01 · Callos Andrew sold $1.1M2026-05-01 · Callos Andrew sold $1.0M2026-04-30 · Callos Andrew sold $948.9K2026-02-05 · Callos Andrew sold $929.0K2026-03-05 · Callos Andrew sold $928.0K2026-01-05 · Callos Andrew sold $904.2K2026-05-05 · Callos Andrew sold $875.5K2026-03-17 · Blum Robert I sold $787.6K2026-08-31 · Callos Andrew sold $702.4K2026-03-05 · Callos Andrew sold $680.7K2026-07-01 · Blum Robert I sold $636.9K2026-07-13 · Blum Robert I sold $614.3K2026-07-27 · Blum Robert I sold $606.5K2026-05-14 · Blum Robert I sold $584.4K2026-05-27 · Blum Robert I sold $579.1K2026-08-10 · Blum Robert I sold $575.7K2025-12-02 · HENDERSON JOHN T sold $559.1K2026-06-15 · Blum Robert I sold $528.5K2026-08-31 · Blum Robert I sold $526.8K2026-04-01 · Blum Robert I sold $499.7K2026-04-15 · Callos Andrew sold $491.8K2026-04-15 · Blum Robert I sold $490.3K2026-03-09 · Blum Robert I sold $481.6K2026-03-17 · Malik Fady Ibraham sold $474.6K2026-04-29 · Blum Robert I sold $447.1K2025-10-06 · Kaye Edward M. MD sold $405.4K2026-06-01 · PARSHALL B LYNNE sold $370.4K2025-09-30 · Kaye Edward M. MD sold $368.8K2026-09-01 · PARSHALL B LYNNE sold $357.4K2026-03-17 · Callos Andrew sold $349.7K2025-09-02 · Kaye Edward M. MD sold $337.8K2025-11-11 · Kaye Edward M. MD sold $336.8K2025-11-19 · PARSHALL B LYNNE sold $323.6K2026-09-01 · B LYNNE PARSHALL filed to sell $354.6K2026-07-30 · ANDREW CALLOS filed to sell $1.9M2026-07-07 · FADY MALIK filed to sell $2.1M2026-07-01 · ROBERT BLUM filed to sell $4.5M2026-06-29 · Sung Lee filed to sell $781.1K2026-06-26 · Sung Lee filed to sell $541.0K2026-06-24 · Sung Lee filed to sell $3.1M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $28.6M sold by insiders over 180 days, 329 funds added last quarter, 1 Congress member(s) bought in 12 months, $13.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CYTOKINETICS INC insiders sold a net $28.6M of stock across 352 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
PARSHALL B LYNNE
Director
SELL
2026-09-01
5,000.0
$357.4K
Blum Robert I
President & CEO
SELL
2026-08-31
7,500.0
$526.8K
Callos Andrew
EVP, Chief Commercial Officer
SELL
2026-08-31
10,000.0
$702.4K
Malik Fady Ibraham
EVP Research & Development
SELL
2026-08-18
3,500.0
$265.4K
Blum Robert I
President & CEO
SELL
2026-08-10
7,500.0
$575.7K
352 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 347 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
20,094,362.0 sh
$1.7B
WELLINGTON MANAGEMENT GROUP LLP
6,931,770.0 sh
$590.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,711,799.0 sh
$571.8M
STATE STREET CORP
6,494,233.0 sh
$553.2M
VANGUARD CAPITAL MANAGEMENT LLC
6,117,515.0 sh
$521.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
B LYNNE PARSHALL
FILED 2026-09-01
$354.6K
ANDREW CALLOS
FILED 2026-07-30
$1.9M
FADY MALIK
FILED 2026-07-07
$2.1M
ROBERT BLUM
FILED 2026-07-01
$4.5M
Sung Lee
FILED 2026-06-29
$781.1K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Thornburg Focus Growth Fund
$5.4M POSITION · AS OF 2026-03-31
2.8%
Eventide Healthcare & Life Sciences Fund
$31.6M POSITION · AS OF 2026-03-31
2.0%
T. Rowe Price Health Care ETF
$311.2K POSITION · AS OF 2026-03-31
1.5%
Tema Heart & Health ETF
$815.6K POSITION · AS OF 2026-02-28
1.5%
Brown Advisory Sustainable Small-Cap Core Fund
$1.5M POSITION · AS OF 2026-03-31
1.4%
F/m Emerald Life Sciences Innovation ETF
$1.3M POSITION · AS OF 2026-02-28
1.4%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 16 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release
5
Phase 1
0 ACTIVE
2
Phase 2
1 ACTIVE
7
Phase 3
2 ACTIVE
2
Multi-phase
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Mr. Blum
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$8.8M
$20.7M
$2.9M
+687%
+15%
2022
$8.5M
$8.7M
$2.3M
+332%
+11%
2021
$6.4M
$19.9M
$2.7M
+330%
+25%
2020
$5.1M
$11.0M
$1.8M
+96%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$88.0M$18.5M$7.5M$94.6M
OPERATING INCOME$-612.3M$-536.2M$-496.2M$-324.2M
NET INCOME$-785.0M$-589.5M$-526.2M$-389.0M
EPS (DILUTED)-6.54-5.26-5.45-4.33
OPERATING CASH FLOW$-510.0M$-395.9M$-414.3M$-299.5M
CASH$122.5M$94.9M$113.0M$65.6M
LONG-TERM DEBT$246.4M$93.2M$58.4M$63.8M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →